Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
Rheumatology and Therapy|March 18, 2024
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARERoy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
The Journal of Rheumatology|March 23, 2002
Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral)Ann VanderBorght, Filip De Keyser, Piet Geusens, et al.
Rheumatology (Oxford, England)|November 20, 2013
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitisCarmen Stolwijk, Astrid van Tubergen, Sofia Ramiro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 13, 2021
The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral SpondyloarthritisThomas Renson, Philippe Carron, Ann-Sophie De Craemer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Brief Report: Dialister as a Microbial Marker of Disease Activity in SpondyloarthritisRaul Y Tito, Heleen Cypers, Marie Joossens, et al.
Rheumatology (Oxford, England)|October 31, 2019
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA studyCarmen Stolwijk, Ivette Essers, Filip van den Bosch, et al.
Clinical and Experimental Rheumatology|February 24, 2023
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populationsSilvia Scriffignano, Rik Lories, Adrien Nzeusseu Toukap, et al.
Annals of the Rheumatic Diseases|May 7, 2021
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)Robert Bm Landewé, Lianne S Gensler, Denis Poddubnyy, et al.
RMD Open|January 31, 2025
Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA studyRodolfo Perez-Alamino, Hernan Maldonado-Ficco, Anna Moltó, et al.
RMD Open|March 4, 2025
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established diseaseVictoria Navarro-Compán, Filip Van den Bosch, Percival Degrava Sampaio-Barros, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
Rheumatology and Therapy|March 18, 2024
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARERoy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
The Journal of Rheumatology|March 23, 2002
Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral)Ann VanderBorght, Filip De Keyser, Piet Geusens, et al.
Rheumatology (Oxford, England)|November 20, 2013
Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitisCarmen Stolwijk, Astrid van Tubergen, Sofia Ramiro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 13, 2021
The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral SpondyloarthritisThomas Renson, Philippe Carron, Ann-Sophie De Craemer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Brief Report: Dialister as a Microbial Marker of Disease Activity in SpondyloarthritisRaul Y Tito, Heleen Cypers, Marie Joossens, et al.
Rheumatology (Oxford, England)|October 31, 2019
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA studyCarmen Stolwijk, Ivette Essers, Filip van den Bosch, et al.
Clinical and Experimental Rheumatology|February 24, 2023
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populationsSilvia Scriffignano, Rik Lories, Adrien Nzeusseu Toukap, et al.
Annals of the Rheumatic Diseases|May 7, 2021
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)Robert Bm Landewé, Lianne S Gensler, Denis Poddubnyy, et al.
RMD Open|January 31, 2025
Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA studyRodolfo Perez-Alamino, Hernan Maldonado-Ficco, Anna Moltó, et al.
RMD Open|March 4, 2025
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established diseaseVictoria Navarro-Compán, Filip Van den Bosch, Percival Degrava Sampaio-Barros, et al.
Pageof 20